Advanced Enzyme Technologies Limited (ADVENZYMES) - Net Assets
Based on the latest financial reports, Advanced Enzyme Technologies Limited (ADVENZYMES) has net assets worth Rs15.34 Billion INR (≈ $165.85 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs16.92 Billion ≈ $182.97 Million USD) and total liabilities (Rs1.58 Billion ≈ $17.12 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ADVENZYMES asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs15.34 Billion |
| % of Total Assets | 90.64% |
| Annual Growth Rate | 25.26% |
| 5-Year Change | 42.48% |
| 10-Year Change | 418.16% |
| Growth Volatility | 18.86 |
Advanced Enzyme Technologies Limited - Net Assets Trend (2008–2025)
This chart illustrates how Advanced Enzyme Technologies Limited's net assets have evolved over time, based on quarterly financial data. Also explore ADVENZYMES total assets for the complete picture of this company's asset base.
Annual Net Assets for Advanced Enzyme Technologies Limited (2008–2025)
The table below shows the annual net assets of Advanced Enzyme Technologies Limited from 2008 to 2025. For live valuation and market cap data, see Advanced Enzyme Technologies Limited market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs14.69 Billion ≈ $158.83 Million |
+7.12% |
| 2024-03-31 | Rs13.71 Billion ≈ $148.28 Million |
+6.77% |
| 2023-03-31 | Rs12.84 Billion ≈ $138.88 Million |
+12.61% |
| 2022-03-31 | Rs11.40 Billion ≈ $123.33 Million |
+10.63% |
| 2021-03-31 | Rs10.31 Billion ≈ $111.47 Million |
+18.83% |
| 2020-03-31 | Rs8.67 Billion ≈ $93.81 Million |
+23.08% |
| 2019-03-31 | Rs7.05 Billion ≈ $76.22 Million |
+21.17% |
| 2018-03-31 | Rs5.82 Billion ≈ $62.91 Million |
+23.10% |
| 2017-03-31 | Rs4.73 Billion ≈ $51.10 Million |
+66.71% |
| 2016-03-31 | Rs2.83 Billion ≈ $30.65 Million |
+30.96% |
| 2015-03-31 | Rs2.16 Billion ≈ $23.41 Million |
+26.53% |
| 2014-03-31 | Rs1.71 Billion ≈ $18.50 Million |
+3.09% |
| 2013-03-31 | Rs1.66 Billion ≈ $17.94 Million |
+68.61% |
| 2012-03-31 | Rs984.09 Million ≈ $10.64 Million |
+52.49% |
| 2011-03-31 | Rs645.35 Million ≈ $6.98 Million |
+31.90% |
| 2010-03-31 | Rs489.29 Million ≈ $5.29 Million |
+28.82% |
| 2009-03-31 | Rs379.81 Million ≈ $4.11 Million |
+18.99% |
| 2008-03-31 | Rs319.19 Million ≈ $3.45 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Advanced Enzyme Technologies Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1153079000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs11.53 Billion | 81.15% |
| Common Stock | Rs223.76 Million | 1.57% |
| Other Comprehensive Income | Rs1.61 Billion | 11.36% |
| Other Components | Rs840.22 Million | 5.91% |
| Total Equity | Rs14.21 Billion | 100.00% |
Advanced Enzyme Technologies Limited Competitors by Market Cap
The table below lists competitors of Advanced Enzyme Technologies Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DBV Technologies S.A.
PA:DBV
|
$420.88 Million |
|
Poongsan Holdi
KO:005810
|
$421.00 Million |
|
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
|
$421.14 Million |
|
Zhejiang Wanfeng Chemical Co. Ltd. A
SHG:603172
|
$421.19 Million |
|
Suzhou Harmontronics Auto Tech Co Ltd
SHG:688022
|
$420.79 Million |
|
The York Water Company
NASDAQ:YORW
|
$420.77 Million |
|
Concord Securities Co Ltd
TWO:6016
|
$420.73 Million |
|
MediaAlpha Inc.
NYSE:MAX
|
$420.67 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Advanced Enzyme Technologies Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 13,241,280,000 to 14,208,630,000, a change of 967,350,000 (7.3%).
- Net income of 1,311,150,000 contributed positively to equity growth.
- Dividend payments of 590,300,000 reduced retained earnings.
- Share repurchases of 3,780,000 reduced equity.
- New share issuances of 3,780,000 increased equity.
- Other comprehensive income increased equity by 212,450,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs1.31 Billion | +9.23% |
| Dividends Paid | Rs590.30 Million | -4.15% |
| Share Repurchases | Rs3.78 Million | -0.03% |
| Share Issuances | Rs3.78 Million | +0.03% |
| Other Comprehensive Income | Rs212.45 Million | +1.5% |
| Other Changes | Rs34.05 Million | +0.24% |
| Total Change | Rs- | 7.31% |
Book Value vs Market Value Analysis
This analysis compares Advanced Enzyme Technologies Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.74x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 119.22x to 2.74x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-03-31 | Rs2.92 | Rs347.70 | x |
| 2009-03-31 | Rs3.45 | Rs347.70 | x |
| 2010-03-31 | Rs4.40 | Rs347.70 | x |
| 2011-03-31 | Rs6.10 | Rs347.70 | x |
| 2012-03-31 | Rs9.34 | Rs347.70 | x |
| 2013-03-31 | Rs15.33 | Rs347.70 | x |
| 2014-03-31 | Rs15.38 | Rs347.70 | x |
| 2015-03-31 | Rs19.47 | Rs347.70 | x |
| 2016-03-31 | Rs25.55 | Rs347.70 | x |
| 2017-03-31 | Rs41.56 | Rs347.70 | x |
| 2018-03-31 | Rs50.07 | Rs347.70 | x |
| 2019-03-31 | Rs60.76 | Rs347.70 | x |
| 2020-03-31 | Rs75.10 | Rs347.70 | x |
| 2021-03-31 | Rs86.77 | Rs347.70 | x |
| 2022-03-31 | Rs97.31 | Rs347.70 | x |
| 2023-03-31 | Rs110.46 | Rs347.70 | x |
| 2024-03-31 | Rs118.35 | Rs347.70 | x |
| 2025-03-31 | Rs126.81 | Rs347.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Advanced Enzyme Technologies Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.23%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 20.59%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.14x
- Recent ROE (9.23%) is below the historical average (18.60%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 15.95% | 8.28% | 0.67x | 2.86x | Rs18.88 Million |
| 2009 | 18.68% | 8.33% | 0.90x | 2.51x | Rs32.57 Million |
| 2010 | 23.97% | 10.11% | 1.04x | 2.28x | Rs66.84 Million |
| 2011 | 26.35% | 14.36% | 0.75x | 2.43x | Rs103.44 Million |
| 2012 | 34.86% | 19.71% | 0.49x | 3.61x | Rs240.72 Million |
| 2013 | 30.49% | 22.70% | 0.55x | 2.42x | Rs334.81 Million |
| 2014 | 11.79% | 9.20% | 0.53x | 2.43x | Rs29.94 Million |
| 2015 | 24.05% | 22.95% | 0.53x | 1.96x | Rs297.82 Million |
| 2016 | 27.28% | 25.92% | 0.65x | 1.62x | Rs480.40 Million |
| 2017 | 19.70% | 27.46% | 0.57x | 1.25x | Rs446.33 Million |
| 2018 | 16.11% | 23.22% | 0.53x | 1.31x | Rs341.47 Million |
| 2019 | 16.36% | 26.59% | 0.52x | 1.19x | Rs431.75 Million |
| 2020 | 15.40% | 29.28% | 0.45x | 1.17x | Rs453.29 Million |
| 2021 | 15.03% | 29.16% | 0.43x | 1.19x | Rs488.65 Million |
| 2022 | 10.99% | 22.61% | 0.42x | 1.16x | Rs107.23 Million |
| 2023 | 8.55% | 19.54% | 0.38x | 1.15x | Rs-178.68 Million |
| 2024 | 10.07% | 21.38% | 0.41x | 1.16x | Rs8.92 Million |
| 2025 | 9.23% | 20.59% | 0.39x | 1.14x | Rs-109.71 Million |
Industry Comparison
This section compares Advanced Enzyme Technologies Limited's net assets metrics with peer companies in the Specialty Chemicals industry.
Industry Context
- Industry: Specialty Chemicals
- Average net assets among peers: $8,964,076,723
- Average return on equity (ROE) among peers: 12.59%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Advanced Enzyme Technologies Limited (ADVENZYMES) | Rs15.34 Billion | 15.95% | 0.10x | $420.87 Million |
| Aarti Industries Limited (AARTIIND) | $16.55 Billion | 20.11% | 1.65x | $1.99 Billion |
| Aarti Surfactants Limited (AARTISURF) | $1.11 Billion | 1.88% | 1.36x | $37.34 Million |
| ABM International Limited (ABMINTLLTD) | $161.33 Million | 4.08% | 2.02x | $4.23 Million |
| Aether Industries Limited (AETHER) | $22.26 Billion | 7.12% | 0.19x | $1.68 Billion |
| Akzo Nobel India Limited (AKZOINDIA) | $9.20 Billion | 20.25% | 0.96x | $1.45 Billion |
| Alkali Metals Limited (ALKALI) | $528.67 Million | 5.51% | 1.00x | $7.38 Million |
| Alkyl Amines Chemicals Limited (ALKYLAMINE) | $980.47 Million | 17.95% | 1.88x | $838.56 Million |
| Ami Organics Limited (AMIORG) | $576.82 Million | 32.06% | 1.70x | $1.18 Billion |
| Anupam Rasayan India Limited (ANURAS) | $29.31 Billion | 4.39% | 0.57x | $1.65 Billion |
About Advanced Enzyme Technologies Limited
Advanced Enzyme Technologies Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of enzymes and probiotics in India, Europe, the United States, Asia, and internationally. The company offers enzymes and probiotics-based nutritional supplements for human healthcare and nutrition, animal nutrition, fruit and vegetable processing, baking, brewing … Read more